Immunocore Holdings Ltd

Stock Chart, Company Information, and Scan Results

$33.16(as of Jul 31, 12:54 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Immunocore Holdings Ltd Company Information, Fundamentals, and Technical Indicators

Stock Price$33.16
Ticker SymbolIMCR
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees493
CountyUSA
Market Cap$1,703.4M
EBIDTA-25.5M
10-Day Moving Average35.44
P/E Ratio-80.47
20-Day Moving Average34.86
Forward P/E Ratio0.00
50-Day Moving Average34.17
Earnings per Share-0.43
200-Day Moving Average31.32
Profit Margin5.35%
RSI43.37
Shares Outstanding50.2M
ATR1.51
52-Week High40.15
Volume312,393
52-Week Low23.15
Most Recent Support Level33.36
Book Value378.5M
Most Recent Resistance Level36.20
P/B Ratio4.60
Upper Keltner38.25
P/S Ratio5.22
Lower Keltner31.47
Debt-to-Equity Ratio38.25
Next Earnings Date08/06/2025
Cash Surplus327.7M
Next Ex-Dividend DateUnknown

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 3 clinical trial to treat advanced cutaneous melanoma and adjuvant uveal melanoma; and brenetafusp that is in Phase 3 clinical trial to treat first-line advanced cutaneous melanoma and in a Phase 1/2 clinical trial in multiple tumor types. In addition, the company's products under development include IMC-R117C (PIWIL-1) that is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, including colorectal cancer; IMC-P115C (PRAME-HLE-A02) that is in Phase 1 clinical trial for patients with tumors that express PRAME; IMC-M113V that is in Phase 1 clinical trials for a potential functional cure in human immunodeficiency virus (HIV); and IMC-I109V that is in Phase 1 clinical trials for a potential functional cure in hepatitis B virus (HBV). Further, it develops IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-S118AI to treat type 1 diabetes; and IMC-U120AI to treat atopic dermatitis. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Immunocore Holdings Ltd In Our Stock Scanner

As of Jul 31, 2025
example chart graphic
Scan Name: Increasing Book ValueScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Increasing Profit MarginScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.